Heterocyclic derivative having PGD2 receptor antagonist activity

Patent metadata

Field	Value
Publication number	US-9725442-B2
Application number	US-201214351234-A
Country	US
Kind code	B2
Filing date	Oct 24, 2012
Priority date	Oct 25, 2011
Publication date	Aug 8, 2017
Grant date	Aug 8, 2017

Abstract

The present invention is related to a compound represented by formula (I),

wherein X 1 , X 2 , X 3 , X 4 , X 5 , R 5 , R 6 , R 7 , R 8 , n, p, q, ring A and ring B are as described in the specification, or a pharmaceutically acceptable salt thereof.

First claim

The invention claimed is:

1. A compound of general formula (I) or a pharmaceutically acceptable salt thereof:

wherein ring A is a formula of:

wherein m and r are independently 1 or 2; and
wherein each R 6 is independently a halogen, cyano, substituted alkyl or unsubstituted alkyl;

wherein ring B is:

wherein R 7 is halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted non-aromatic carbocyclyl, substituted or unsubstituted aromatic carbocyclyl oxy or substituted or unsubstituted non-aromatic carbocyclyl oxy;

wherein —X 1 ═ is —C(R 1 )═;
wherein —X 2 ═ is —C(R 2 )═;
wherein —X 3 ═ is —C(R 3 )═;
wherein —X 4 ═ is —C(R 4 )═;
wherein —X 5 ═ is —N═; and
wherein R 5 of the following formula (i) is formula: -L-R 9 ; such that:

wherein R 1 of formula (i-1) is a hydrogen atom or halogen;
wherein R 2 of formula (i-1) is a hydrogen atom, halogen, substituted alkyl or unsubstituted alkyl;
wherein R 3 of formula (i-1) is a hydrogen atom, halogen, substituted alkyl or unsubstituted alkyl;
wherein R 4 of formula (i-1) is a hydrogen atom;
wherein -L- of formula (i-1) is substituted or unsubstituted methylene; and
wherein R 9 of formula (i-1) is carboxy;

wherein n is 1 or 2;
wherein q is 0; and
wherein p is 0 or 1.

2. A pharmaceutical composition comprising the compound of claim 1 or the pharmaceutically acceptable salt thereof.

3. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , which is represented by one of the following structural formulas:

4. A pharmaceutical composition comprising the compound or the phaimaceutically acceptable salt thereof of claim 3 .

5. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , which is represented by the following structural formula:

6. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , which is represented by the following structural formula:

7. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , which is represented by the following structural formula:

8. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , which is represented by the following structural formula:

9. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , which is represented by the following structural formula:

10. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , which is represented by the following structural formula:

11. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , which is represented by the following structural formula:

12. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , which is represented by the following structural formula:

13. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , which is represented by the following structural formula:

14. The compound or the pharmaceutically acceptable salt thereof according to claim 1 , which is represented by the following structural formula:

15. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof of claim 5 .

16. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof of claim 6 .

17. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof of claim 7 .

18. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof of claim 8 .

19. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof of claim 9 .

20. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof of claim 10 .

21. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof of claim 11 .

22. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof of claim 12 .

23. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof of claim 13 .

24. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof of claim 14 .

Assignees

• Shionogi & Co

Inventors

• Hata Kayoko
• Masuda Manami
• Nakai Hiromi
• Taniyama Daisuke
• Tobinaga Hiroyuki
• Hato Yoshio
• Fujiu Motohiro

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P33/12

  Schistosomicides · CPC title